<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676780</url>
  </required_header>
  <id_info>
    <org_study_id>H04-176</org_study_id>
    <nct_id>NCT00676780</nct_id>
  </id_info>
  <brief_title>Green Tea Extract and Prostate Cancer</brief_title>
  <official_title>Green Tea Extract and Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center Shreveport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polyphenon Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center Shreveport</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if a green tea extract can beneficially alter several
      markers of cancer risk and progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the short-term effects of a daily dose of Polyphenon E administered during the
      interval between prostate biopsy and radical prostatectomy in men with recently diagnosed
      prostate cancer. Endpoints will be changes in serum and tissue biomarkers related to
      progression of cancer.

      The effect of Polyphenon E on tumor cell c-Met expression and phosphorylation is the primary
      objective. Secondary objectives include the effects on the other tissue and serum biomarkers.
      Evaluation of the safety and tolerability of Polyphenon E in this subject population is
      another objective.

      1.1 Determine the effects of Polyphenon E on tumor cell c-Met expression and phosphorylation
      levels in patients with prostate cancer 1.2 Determine the effects of Polyphenon E on PI-3K
      activation in patients with prostate cancer 1.3 Determine the effects of Polyphenon E on MAPK
      activation in patients with prostate cancer 1.4 Determine the effects of Polyphenon E on
      expression levels of other proteins involved in motility and invasion such as Rho GTPases and
      extracellular proteinases in patients with prostate cancer 1.5 Determine the effects of
      Polyphenon E on markers of angiogenesis in patients with prostate cancer 1.6 Determine the
      effects of Polyphenon E on serum Prostate Specific Antigen (PSA) in patients with prostate
      cancer 1.7 Determine the effects of Polyphenon E on other serum markers: C-reactive protein
      (CRP), Insulin-Like Growth factor I (IGF-I), Insulin-like Growth Factor Binding Protein 3
      (IGFBP-3), Hepatocyte Growth Factor HGF 1.8 Evaluate the safety and tolerability of
      Polyphenon E in this subject population
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in serum prostate specific antigen (PSA) from baseline to post Polyphenol E treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Vascular Endothelial Growth Factor (VEGF) and Prostate Cancer.</measure>
    <time_frame>Baseline and 6 weeks.</time_frame>
    <description>Change in serum vascular endothelial growth factor (VEGF) from baseline to post Polyphenol E treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Hepatocyte Growth Factor (HGF) and Prostate Cancer.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in serum hepatocyte growth factor (HGF) from baseline to post Polyphenol E treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ECGC Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm for a phase II study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyphenon E (EGCG)</intervention_name>
    <description>4 capsules daily with a meal for the duration of the study</description>
    <arm_group_label>ECGC Extract</arm_group_label>
    <other_name>Polyphenon E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recent biopsy positive for prostate cancer

          -  scheduled for prostatectomy

          -  must be able to swallow capsules

          -  Palpable mass by digital rectal examination (DRE)

          -  Ability to give informed consent and willingness to adhere to study protocol

          -  Age â‰¥ 18 years and less than 75

        Exclusion Criteria:

          -  abnormal liver function

          -  Prior hormonal or surgical therapy for prostate cancer

          -  Liver or kidney problems that would interfere with metabolism of study drug

          -  Any condition that would hamper informed consent or ability to comply with study
             protocol

          -  Participation in another research study in the last three months

          -  Known malignancy at any site other than prostate

          -  Recent consumption of green tea (5 or more cups per day, within one week prior to
             biopsy)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry W McLarty, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSUHSC Shreveport</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009 Jul;2(7):673-82. doi: 10.1158/1940-6207.CAPR-08-0167. Epub 2009 Jun 19.</citation>
    <PMID>19542190</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <results_first_submitted>August 29, 2011</results_first_submitted>
  <results_first_submitted_qc>June 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2012</results_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center Shreveport</investigator_affiliation>
    <investigator_full_name>Jerry McLarty</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>EGCG</keyword>
  <keyword>polyphenols</keyword>
  <keyword>biomarkers</keyword>
  <keyword>prostate specific antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the urology clinic at LSU Health, Shreveport during the period of May 1, 2004 and February 20, 2008.</recruitment_details>
      <pre_assignment_details>Exclusion criterias were determined before enrollment process.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ECGC Extract, Prostate Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and prostate cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ECGC Extract, Prostate Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and prostate cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer</title>
        <description>Change in serum prostate specific antigen (PSA) from baseline to post Polyphenol E treatment.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>The number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ECGC Extract</title>
            <description>Single arm for a phase II study of the effects of Epigallocatechin Gallate (ECGC) polyphenol extract from green tea on biomarkers in patients with prostate cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer</title>
          <description>Change in serum prostate specific antigen (PSA) from baseline to post Polyphenol E treatment.</description>
          <population>The number of participants for analysis was determined per protocol.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.0425" upper_limit="2.4675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.027</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Vascular Endothelial Growth Factor (VEGF) and Prostate Cancer.</title>
        <description>Change in serum vascular endothelial growth factor (VEGF) from baseline to post Polyphenol E treatment.</description>
        <time_frame>Baseline and 6 weeks.</time_frame>
        <population>The number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ECGC Extract</title>
            <description>Single arm for a phase II study of the effects of ECGC polyphenol extract from green tea on biomarkers in patients with prostate cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Vascular Endothelial Growth Factor (VEGF) and Prostate Cancer.</title>
          <description>Change in serum vascular endothelial growth factor (VEGF) from baseline to post Polyphenol E treatment.</description>
          <population>The number of participants for analysis was determined per protocol.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="-6.315" upper_limit="123.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Hepatocyte Growth Factor (HGF) and Prostate Cancer.</title>
        <description>Change in serum hepatocyte growth factor (HGF) from baseline to post Polyphenol E treatment.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ECGC Extract</title>
            <description>Epigallocatechin Gallate (ECGC) Single arm for a phase II study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Hepatocyte Growth Factor (HGF) and Prostate Cancer.</title>
          <description>Change in serum hepatocyte growth factor (HGF) from baseline to post Polyphenol E treatment.</description>
          <population>Number of participants for analysis was determined per protocol.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.67" lower_limit="27.0837" upper_limit="358.7475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no change, i.e. median change = 0.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ECGC Extract, Prostate Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and prostate cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Subject suffered a heart attack prior to surgery procedure. Determined to be not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patient compliance was an issue.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jerry W. McLarty, Ph.D.</name_or_title>
      <organization>LSUShreveport</organization>
      <phone>(318)813-1446</phone>
      <email>jmclar@lsuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

